Oragenics Inc (OGEN)
0.55
-0.01 -1.84%
NYSE AM
Dec 5, 14:12
Real time
USD
Oragenics Outperform Recommendations
View 4,000+ financial data types
Browse...
View Full Chart
Outperform Recommendations Chart
Historical Outperform Recommendations Data
View and export this data going back to 2014.
Start your Free Trial
Export Data
Date Range:
Data for this Date Range | |
---|---|
Dec. 3, 2019 | Upgrade |
Dec. 2, 2019 | Upgrade |
Nov. 21, 2019 | Upgrade |
Oct. 2, 2019 | Upgrade |
Oct. 1, 2019 | Upgrade |
Sept. 26, 2019 | Upgrade |
Sept. 5, 2019 | Upgrade |
Aug. 20, 2019 | Upgrade |
Aug. 16, 2019 | Upgrade |
June 7, 2019 | Upgrade |
May 21, 2019 | Upgrade |
May 15, 2019 | Upgrade |
May 3, 2019 | Upgrade |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
View Outperform Recommendations for OGEN
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
Start your free 7-Day Trial.
Start My Free Trial
No credit card required.
Already a subscriber? Sign in.
Outperform Recommendations Benchmarks
Benchmarks | |
---|---|
Agilent Technologies Inc | Upgrade |
Processa Pharmaceuticals Inc | Upgrade |
Abiomed Inc | Upgrade |
Outperform Recommendations Range, Past 5 Years
Minimum | Upgrade | Dec 23 2014 |
Maximum | Upgrade | Apr 26 2019 |
Average | Upgrade |
News
Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019
Business Wire 12/03 08:30 ET
Business Wire 12/03 08:30 ET
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis
Business Wire 12/02 08:30 ET
Business Wire 12/02 08:30 ET
--Analyst Actions: UBS Lifts Price Target on Oragenics to $39 From $31, Maintains Neutral
MT Newswires 11/15 09:50 ET
MT Newswires 11/15 09:50 ET
Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients
Business Wire 09/25 08:00 ET
Business Wire 09/25 08:00 ET